BioCentury
ARTICLE | Company News

CTFH latest to partner with Insilico in AI discovery deal

October 9, 2019 8:10 PM UTC
Updated on Oct 9, 2019 at 9:38 PM UTC

In the latest addition to a growing roster of industry collaborations, AI company Insilico has partnered with CTFH to discover and develop two programs for triple-negative breast cancer.

Insilico Medicine Inc. is eligible to receive up to $200 million from Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. (CTFH), including an upfront payment, milestones and royalties. Details were not disclosed. The partnership adds to a balance sheet bolstered by Insilico’s $37 million series B round in September led by Qiming Venture Partners...

BCIQ Company Profiles

Insilico Medicine Inc.